Cariprazine is an orally active D2/D3 dopamine receptor antagonist exhibits high selectivity and affinity to dopamine D3(Ki=0.09 nM) and D2 (Ki=0.5 nM) receptors and moderate affinity to serotonin 5-HT(1A) receptors. It is used as an antipsychotic drug candidate for the potential treatment of schizophrenia, bipolar mania and depression. It has also been used as a potential adjunct in treatment-resistant major depressive disorder. It had lower affinity at human and rat hippocampal 5-HT(1A) receptors (pK(i) 8.59 and 8.34, respectively) and demonstrated low intrinsic efficacy.Cariprazine displayed low affinity at human 5-HT(2A) receptors (pK(i) 7.73) in vitro. It could reduce the rewarding effect of cocaine and attenuated relapse to cocaine seeking with half maximal effective dose values of 0.2, 4.2, and 0.17 mg/kg, respectively. It was developed by Gedeon Richter and received FDA approval on September 17, 2015 and is currently owned by Gedeon Richter and Actavis. It is in phase III clinical trials in patients with schizophrenia and in patients with bipolar disorder.https://www.bocsci.com/cariprazine-cas-839712-12-8-item-459781.html

BOC Sciences is a brand of BOCSCI Inc. We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-informed decisions tailored to your evolving needs for premium chemicals. Our complete suite of CRO services spans the entire molecule development pipeline including contract research for target identification, building blocks, compound synthesis, biochemical and cellular analysis, preclinical animal tests, and clinical studies.

Products:

BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecule and chiral compounds.

Over eight years of successful operation in the pharmaceutical industry has enabled us to possess a full-bodied array of building blocks in numerous pack sizes. BOC Sciences is constantly seeking to expand our product lines by incorporating additional potential drug like molecules.



Services:

BOC Sciences provides a wide range of services to support the pharmaceutical industry through all stages of drug discovery including Custom Synthesis of those chemicals that are not in stock, Isotope Labeling Service, Chiral Synthesis and Resolution, Bioconjugation, PEGylation services, analytical services.

Our capacity to provide pharmaceutical discovery services across the entire spectrum of the drug discovery process has assisted many of our esteemed clients in reaching their R&D goals. We are actively improving our capabilities and capacity through new expansions in BOC Sciences’s global business.



Manufacturing services:

-> Manufacture of raw materials, registered GMP starting materials and intermediates from small scale (1kg) to commercial quantities (1000 kg);
-> Production of APIs to support drug candidate selections;
-> GLP toxicology studies and clinical studies;
-> Development and optimization of environmentally friendly process;
-> Competitive quality and price comparable to commodity chemical suppliers


Our clients



As a leading provider of building blocks, synthetic intermediates, and custom synthesis, BOC Sciences is committed to supplying cost-effective products and services, which are being utilized by our customers worldwide in molecule discovery on a daily basis to promote innovations in various industries.